2. Academic Validation
  3. Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow's milk

Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow's milk

  • Nat Microbiol. 2025 Apr;10(4):836-840. doi: 10.1038/s41564-025-01961-5.
Jeremy C Jones 1,  Konstantin Andreev 1,  Thomas P Fabrizio 1,  Andrew S Bowman 2,  Elena A Govorkova 1,  Richard J Webby 3
Affiliations

Affiliations

  • 1 Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • 2 Department of Veterinary Preventive Medicine, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
  • 3 Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN, USA. [email protected].
PMID: 40097765 DOI: 10.1038/s41564-025-01961-5
Abstract

Testing approved antivirals against A(H5N1) influenza viruses circulating in peridomestic species, including dairy cows, is critical to public health and pre-pandemic planning. It cannot be tested in humans due to A(H5N1) disease severity. Here, in mice, we demonstrate that US FDA-approved baloxavir treatment mediates improved disease outcomes (survival and viral dissemination) over oseltamivir after lethal intranasal and ocular challenge with A(H5N1)-contaminated cow milk.

Figures
Products